Vorinostat (rINN) also known as suberanilohydroxamic acid is a member of a
larger class of compounds that inhibit histone deacetylases (HDAC).
Jun 13, 2005 ... Description. Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a
drug currently under investigation for the treatment of cutaneous ...
(vor-IN-o-stat). Trade Name: Zolinza. Drug Type: Vorinostat is an anti-cancer ("
antineoplastic" or "cytotoxic") chemotherapy drug. Vorinostat is classified as an ...
Suberoylanilide Hydroxamic Acid is a synthetic hydroxamic acid derivative with
antineoplastic activity. Vorinostat, a second generation polar-planar compound, ...
Structure of vorinostat (suberoylanilide hydroxamic acid, SAHA). Phase I
vorinostat clinical trials were initiated with both an i.v. and an oral drug
formulation [2, 6, ...
Vorinostat is used to treat cutaneous T-cell lymphoma (CTCL, a type of cancer) in
people whose disease has not improved, has gotten worse, or has come back ...
Vorinostat, a second generation polar-planar compound, binds to the catalytic
domain of the histone deacetylases (HDACs). This allows the hydroxamic moiety
Dec 12, 2006 ... Vorinostat (suberoylanilide hydroxamic acid or SAHA) is a nanomolar inhibitor of
HDAC activity that has undergone initial evaluation in multiple ...
Learn about the prescription medication Zolinza (Vorinostat), drug uses, dosage,
side effects, drug interactions, warnings, reviews and patient labeling.
Dec 10, 2015 ... Vorinostat is in a class of anti-cancer therapies called histone deacetylase (
HDAC) inhibitors. Histone deacetylation is a biochemical process ...